Freedom And Capital Drive Intarcia Down Independent Path

With a lucrative and unique royalty financing deal and positive first results from its global Phase III diabetes study, Intarcia has emerged as one of the biotech industry’s most valuable private companies and is in position to control its own destiny. It just may disrupt the type 2 diabetes market in the process.

In the late winter of 2013, around the time Intarcia Therapeutics Inc. was enrolling the first patients in its global Phase III Freedom trials for ITCA 650, its lead product in diabetes, the biotech moved from California to Boston, settling into Seaport offices overlooking the city’s convention center. Intarcia chairman and CEO Kurt Graves says the location was picked with an eye toward the 75th Scientific Sessions of the American Diabetes Association, where in early June Intarcia presented the first successful results from Freedom. Though it “seems like yesterday,” Graves has been looking out those windows for two years. “We just had to pray the data came out the way we wanted it to,” he says.

But back then, Intarcia wasn’t just a couple blocks’ walk and solid Phase III results away from a celebratory ADA meeting. By Graves’ estimation the company also needed about a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

Bringing Israeli Medical Device Candidates To The Right Partners In The US

 
• By 

Despite regional unrest, it is business as usual for medtech innovators and investors in Israel as evidenced by continued high-value M&A of locally developed technologies. Irit Yaniv, co-chair of the medtech session at the upcoming BioMed Israel 2025, explained the unique dynamics of Israeli medtech innovation.

Deals In Depth: April 2025

 
• By 

Four $1bn+ alliances were penned in April, and one exceeded $2bn.

Deals Shaping The Industry, April 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during April 2025. Data courtesy of Biomedtracker.

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By 

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By 

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By 

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.